Sutro Biopharma
STRO
120 hedge funds and large institutions have $753M invested in Sutro Biopharma in 2021 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 45 increasing their positions, 37 reducing their positions, and 14 closing their positions.
1,000% more call options, than puts
Call options by funds: $11K | Put options by funds: $1K
22% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 37
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.31% less ownership
Funds ownership: 8.94% → 8.63% (-0.31%)
2% less capital invested
Capital invested by funds: $766M → $753M (-$13.7M)
3% less funds holding
Funds holding: 124 → 120 (-4)
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
Top Buyers
| 1 |
SCM
Suvretta Capital Management
New York
|
+$9.86M |
| 2 |
FM
Frazier Management
Seattle,
Washington
|
+$8.88M |
| 3 |
Goldman Sachs
New York
|
+$5.21M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$4.6M |
| 5 |
Nomura Holdings
Tokyo,
Japan
|
+$3.98M |
Top Sellers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$14.5M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
-$12.6M |
| 3 |
State Street
Boston,
Massachusetts
|
-$10.1M |
| 4 |
O
OrbiMed
New York
|
-$8.06M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$6.81M |
STRO Hedge Fund Activity: Q3 2021 in Review
120 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q3 2021, worth a combined $753M — down 1.8% from $766M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of STRO and 10 opened new positions — a net loss of 4 holders — while 37 trimmed existing stakes and 45 added.
The largest buyer was Suvretta Capital Management, adding an estimated $9.86M. The largest seller was Point72 Asset Management, cutting an estimated $14.5M.
- 120 institutional investors held Sutro Biopharma (STRO) as of Q3 2021, down from 124 in Q2 2021.
- Funds reported $753M of Sutro Biopharma stock for Q3 2021, down 1.8% quarter-over-quarter.
- 10 funds opened new Sutro Biopharma positions in Q3 2021 and 14 closed out, a net change of -4 holders.
- The largest Sutro Biopharma buyer in Q3 2021 was Suvretta Capital Management, an estimated $9.86M added.
- The largest Sutro Biopharma seller in Q3 2021 was Point72 Asset Management, an estimated $14.5M sold.
Based on aggregated 13F filings for Q3 2021.